<?xml version='1.0' encoding='utf-8'?>
<document id="23054212"><sentence text="Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors."><entity charOffset="37-46" id="DDI-PubMed.23054212.s1.e0" text="pazopanib" /><entity charOffset="51-60" id="DDI-PubMed.23054212.s1.e1" text="lapatinib" /><pair ddi="false" e1="DDI-PubMed.23054212.s1.e0" e2="DDI-PubMed.23054212.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23054212.s1.e0" e2="DDI-PubMed.23054212.s1.e1" /></sentence><sentence text="This phase I, open-label, dose-escalation study assessed the maximum-tolerated dose, safety, pharmacokinetics, and preliminary antitumor activity of pazopanib plus lapatinib combination therapy in patients with solid tumors"><entity charOffset="149-158" id="DDI-PubMed.23054212.s2.e0" text="pazopanib" /><entity charOffset="164-173" id="DDI-PubMed.23054212.s2.e1" text="lapatinib" /><pair ddi="false" e1="DDI-PubMed.23054212.s2.e0" e2="DDI-PubMed.23054212.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23054212.s2.e0" e2="DDI-PubMed.23054212.s2.e1" /></sentence><sentence text=" Patients were to take pazopanib and lapatinib orally once daily in a fasting condition"><entity charOffset="23-32" id="DDI-PubMed.23054212.s3.e0" text="pazopanib" /><entity charOffset="37-46" id="DDI-PubMed.23054212.s3.e1" text="lapatinib" /><pair ddi="false" e1="DDI-PubMed.23054212.s3.e0" e2="DDI-PubMed.23054212.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23054212.s3.e0" e2="DDI-PubMed.23054212.s3.e1" /></sentence><sentence text=" During the escalation phase, pazopanib and lapatinib doses were escalated in serial patient cohorts, and a limited blood sampling scheme was applied for pharmacokinetic evaluation"><entity charOffset="30-39" id="DDI-PubMed.23054212.s4.e0" text="pazopanib" /><entity charOffset="44-53" id="DDI-PubMed.23054212.s4.e1" text="lapatinib" /><pair ddi="false" e1="DDI-PubMed.23054212.s4.e0" e2="DDI-PubMed.23054212.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23054212.s4.e0" e2="DDI-PubMed.23054212.s4.e1" /></sentence><sentence text=" In the expansion phase, potential pharmacokinetic interaction between pazopanib and lapatinib was evaluated more extensively"><entity charOffset="71-80" id="DDI-PubMed.23054212.s5.e0" text="pazopanib" /><entity charOffset="85-94" id="DDI-PubMed.23054212.s5.e1" text="lapatinib" /><pair ddi="false" e1="DDI-PubMed.23054212.s5.e0" e2="DDI-PubMed.23054212.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23054212.s5.e0" e2="DDI-PubMed.23054212.s5.e1" /></sentence><sentence text=" Seventy-five patients were treated" /><sentence text=" Multiple dosing levels were studied, combining pazopanib up to 800 mg/day with lapatinib up to 1,500 mg/day"><entity charOffset="48-57" id="DDI-PubMed.23054212.s7.e0" text="pazopanib" /><entity charOffset="80-89" id="DDI-PubMed.23054212.s7.e1" text="lapatinib" /><pair ddi="false" e1="DDI-PubMed.23054212.s7.e0" e2="DDI-PubMed.23054212.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23054212.s7.e0" e2="DDI-PubMed.23054212.s7.e1" /></sentence><sentence text=" Dose-limiting toxicities observed included grade 3 neutropenia, fatigue, asymptomatic decline in left ventricular ejection fraction, diarrhea, and liver enzyme elevations" /><sentence text=" The most common drug-related adverse events were diarrhea, nausea, anorexia, fatigue, vomiting, rash, hair depigmentation, and hypertension" /><sentence text=" The dose recommended for further evaluation was pazopanib 800 mg plus lapatinib 1,500 mg (paz-800/lap-1500)"><entity charOffset="49-58" id="DDI-PubMed.23054212.s10.e0" text="pazopanib" /><entity charOffset="71-80" id="DDI-PubMed.23054212.s10.e1" text="lapatinib" /><pair ddi="false" e1="DDI-PubMed.23054212.s10.e0" e2="DDI-PubMed.23054212.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23054212.s10.e0" e2="DDI-PubMed.23054212.s10.e1" /></sentence><sentence text=" No clinically significant drug-drug interaction was observed at the paz-400/lap-1000 level" /><sentence text=" However, at paz-800/lap-1500, an increase in both the AUC0-t and Cmax of pazopanib was observed"><entity charOffset="74-83" id="DDI-PubMed.23054212.s12.e0" text="pazopanib" /></sentence><sentence text=" Four partial responses were observed in patients with renal cancer (n=2), giant-cell tumor of the bone (n=1), and thyroid cancer (n=1)" /><sentence text=" Stable disease for â‰¥ 18 weeks was seen in 12 patients" /><sentence text=" Pazopanib and lapatinib can be administered in combination at their respective single-agent doses with an acceptable safety profile"><entity charOffset="1-10" id="DDI-PubMed.23054212.s15.e0" text="Pazopanib" /><entity charOffset="15-24" id="DDI-PubMed.23054212.s15.e1" text="lapatinib" /><pair ddi="false" e1="DDI-PubMed.23054212.s15.e0" e2="DDI-PubMed.23054212.s15.e0" /><pair ddi="false" e1="DDI-PubMed.23054212.s15.e0" e2="DDI-PubMed.23054212.s15.e1" /></sentence><sentence text=" Further evaluation of the combination will be pursued, exploring both paz-800/lap-1500 and paz-400/lap-1000" /><sentence text="" /></document>